Want to see ELAB full AI Analyst Report?
Top Page
PMGC Holdings
(NASDAQ:ELAB)
Select Model
Select Model
Rating:47Neutral
Price Target:
$0.90
▼(-42.06% Downside)
Action:Reiterated
Date:07/10/26
The score is primarily held down by weak financial performance (large losses, thin margins, and ongoing cash burn) and a bearish technical setup (below major moving averages with negative MACD). Corporate events are constructive and provide strategic/financing support, but potential dilution and the lack of earnings-based valuation support limit the uplift.
Positive Factors
Revenue Growth
A ~116% TTM top-line rebound demonstrates meaningful commercial traction and expanding demand across PMGC’s businesses. Durable revenue growth improves the prospect of scaling fixed-cost coverage, supports future investment in R&D and integration of acquisitions, and underpins recovery potential if margins are restored.
Negative Factors
Persistent Cash Burn
Consistent negative operating and free cash flow highlights ongoing reliance on external financing to fund operations and R&D. Over a multi-month horizon this limits strategic optionality, increases dilution or debt risk if losses persist, and constrains the company’s ability to self-fund clinical programs or capex without new capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
A ~116% TTM top-line rebound demonstrates meaningful commercial traction and expanding demand across PMGC’s businesses. Durable revenue growth improves the prospect of scaling fixed-cost coverage, supports future investment in R&D and integration of acquisitions, and underpins recovery potential if margins are restored.
Read all positive factors
PMGC Holdings (ELAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.19M
Dividend YieldN/A
Average Volume (3M)89.87K
Price to Earnings (P/E)―
Beta (1Y)2.69
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees34
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,543,751
10 Day Avg. Volume35,159
30 Day Avg. Volume89,868
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.37
Price to Sales (P/S)4.90
P/FCF Ratio-0.45
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PMGC Holdings Business Overview & Revenue Model
Company Description
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critic...
PMGC Holdings Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.27M | 590.08K | 2.47M | 1.71M | 766.28K | 827.00 |
| Gross Profit | 161.28K | 74.81K | 1.80M | 1.13M | 447.31K | -2.02K |
| EBITDA | -9.03M | -7.27M | -3.20M | -3.66M | -1.79M | -782.30K |
| Net Income | -11.11M | -7.71M | -6.25M | -4.30M | -1.80M | -784.74K |
Balance Sheet | ||||||
| Total Assets | 26.03M | 12.87M | 8.99M | 5.19M | 1.89M | 666.25K |
| Cash, Cash Equivalents and Short-Term Investments | 15.09M | 5.40M | 3.98M | 3.33M | 1.15M | 411.86K |
| Total Debt | 7.96M | 2.64M | 0.00 | 210.49K | 283.22K | 0.00 |
| Total Liabilities | 13.43M | 5.03M | 2.33M | 1.36M | 760.87K | 215.62K |
| Stockholders Equity | 12.61M | 7.84M | 6.66M | 3.83M | 1.13M | 450.63K |
Cash Flow | ||||||
| Free Cash Flow | -8.37M | -6.38M | -5.49M | -4.57M | -1.62M | -693.42K |
| Operating Cash Flow | -7.57M | -5.93M | -5.49M | -4.56M | -1.59M | -660.93K |
| Investing Cash Flow | -5.03M | -2.77M | -610.56K | -11.19K | -32.03K | -32.48K |
| Financing Cash Flow | 21.59M | 10.12M | 6.76M | 6.74M | 2.36M | 1.09M |
PMGC Holdings Technical Analysis
Negative
1.55
Price Trends
1.29
Negative
2.34
Negative
34.74
Negative
Market Momentum
-0.12
Negative
41.29
Neutral
52.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELAB, the sentiment is Negative. The current price of 1.55 is above the 20-day moving average (MA) of 1.01, above the 50-day MA of 1.29, and below the 200-day MA of 34.74, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 41.29 is Neutral, neither overbought nor oversold. The STOCH value of 52.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ELAB.
PMGC Holdings Risk Analysis
PMGC Holdings disclosed 79 risk factors in its most recent earnings report. PMGC Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PMGC Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $4.87M | >-0.01 | -72.72% | ― | -34.06% | 79.61% | |
49 Neutral | $8.50M | -0.20 | -238.69% | ― | ― | 99.30% | |
47 Neutral | $4.19M | >-0.01 | -82.41% | ― | ― | ― | |
43 Neutral | $146.08M | -0.20 | -1028.81% | ― | ― | 61.43% | |
42 Neutral | $5.96B | >-0.01 | -55.81% | ― | ― | 88.07% |
* Healthcare Sector Average
ELAB
PMGC Holdings
0.98
-159.46
-99.39%
BDRX
Biodexa Pharmaceuticals
1.49
-32.31
-95.59%
INDP
Indaptus Therapeutics
1.36
-5.86
-81.16%
INM
InMed Pharmaceuticals
1.49
-0.78
-34.36%
CNSP
CNS Pharmaceuticals
5.36
-2.09
-28.05%
PMGC Holdings Corporate Events
Business Operations and StrategyM&A Transactions
PMGC Holdings Streamlines Aerospace Operations Through Subsidiary Merger
Positive
Jul 9, 2026
On July 2, 2026, AGA Precision Systems LLC and AB Aerospace, Inc., both wholly owned subsidiaries of PMGC Holdings Inc., entered into a merger agreement under which AGA will be merged into AB. The transaction is structured so that AB will be the s...
Business Operations and StrategyRegulatory Filings and Compliance
PMGC Holdings Secures Key Aerospace Defense IP License
Positive
Jul 7, 2026
As of June 30, 2026, NorthStrive Defense Tech LLC entered into a worldwide, non-transferable exclusive license agreement with a third-party licensor covering U.S. Patent No. 12,291,334 and associated know-how in aerospace and defense technologies....
Business Operations and Strategy
PMGC Advances AI-Driven Muscle Drug Discovery Program
Positive
Jul 1, 2026
On July 1, 2026, NorthStrive Biosciences reported positive Phase III results from its AI-driven drug discovery collaboration with Yuva Biosciences, focused on muscle preservation and metabolic stress. The study used Yuva’s MitoNova AI platfo...
Business Operations and StrategyShareholder Meetings
PMGC Holdings Shareholders Approve Governance-Related Bylaw Amendments
Neutral
Jun 8, 2026
On June 5, 2026, PMGC Holdings Inc. reported that a majority of its shareholders approved amendments to the company’s bylaws during its 2026 Annual Meeting of Shareholders, based on voting results certified by Broadridge Financial Solutions ...
Business Operations and Strategy
NorthStrive Secures Key Aerospace and Defense Patent License
Positive
Jun 5, 2026
On June 2, 2026, NorthStrive Defense Tech entered into a binding term sheet with the Florida State University Research Foundation under which it secured an exclusive, worldwide, sublicensable license to U.S. Patent No. 12,291,334 and related know-...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
PMGC Holdings Completes Acquisition of A&B Aerospace Business
Positive
May 13, 2026
On May 12, 2026, PMGC Holdings Inc. completed the acquisition of 100% of AB Aerospace, Inc. for $4.5 million in cash, subject to customary working capital and cash balance adjustments and a $225,000 indemnification holdback tied to pending litigat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.